{
    "hands_on_practices": [
        {
            "introduction": "Effective diagnosis in dermatology often begins with integrating clinical signs with laboratory data. This practice problem guides you through a foundational skill in managing patients with xanthomas: using a standard lipid panel to calculate low-density lipoprotein ($LDL$) cholesterol and correlating the resulting lipid profile with the patient's physical presentation to infer the most likely xanthoma subtype. Mastering this process is essential for identifying underlying severe hypercholesterolemia and initiating appropriate management .",
            "id": "4500504",
            "problem": "A fasting adult presents with yellow papules on extensor surfaces and subtle thickening of the Achilles tendon. A lipid panel reports total cholesterol $TC = 280$ mg/dL, high-density lipoprotein cholesterol $HDL = 40$ mg/dL, and triglycerides $TG = 250$ mg/dL. Assume a fasting sample and that the very-low-density lipoprotein cholesterol $VLDL$ can be approximated by $\\frac{TG}{5}$ (mg/dL) when $TG < 400$ mg/dL. Using the relationship that total cholesterol is approximately the sum of cholesterol carried by $LDL$, $HDL$, and $VLDL$, compute the low-density lipoprotein cholesterol $LDL$ via the Friedewald method. Then, based on established clinicopathologic correlations between lipid fractions and xanthoma subtypes, infer the most likely xanthoma subtype.\n\nFor the purpose of a numerical final answer, encode the inferred xanthoma subtype as an integer code: $1$ for tendinous xanthoma, $2$ for eruptive xanthoma, $3$ for tuberous xanthoma, and $4$ for planar xanthelasma palpebrarum. Express $LDL$ in mg/dL. Report your final result as a $1 \\times 2$ row matrix containing, in order, the computed $LDL$ value and the subtype code. Do not include units in the matrix.",
            "solution": "The problem requires a two-part solution: first, the calculation of the low-density lipoprotein cholesterol ($LDL$) level using the Friedewald method, and second, the inference of the most likely xanthoma subtype based on the provided clinical and laboratory data.\n\nFirst, we validate the problem statement.\nThe givens are:\n- Total cholesterol, $TC = 280$ mg/dL.\n- High-density lipoprotein cholesterol, $HDL = 40$ mg/dL.\n- Triglycerides, $TG = 250$ mg/dL.\n- The sample is from a fasting adult.\n- A clinical presentation of yellow papules on extensor surfaces and subtle thickening of the Achilles tendon.\n- The Friedewald approximation for very-low-density lipoprotein cholesterol ($VLDL$) is given by $VLDL = \\frac{TG}{5}$ in units of mg/dL, which is valid for $TG < 400$ mg/dL.\n- The total cholesterol is the sum of its constituent lipoprotein fractions: $TC \\approx LDL + HDL + VLDL$.\n- A coding scheme for the final answer: tendinous xanthoma ($1$), eruptive xanthoma ($2$), tuberous xanthoma ($3$), and planar xanthelasma palpebrarum ($4$).\n\nThe problem is scientifically grounded, as the Friedewald equation is a standard clinical tool, and the association between dyslipidemia and xanthomas is a fundamental concept in endocrinology and dermatology. The data provided ($TC$, $HDL$, $TG$) are clinically realistic. The condition for using the Friedewald approximation, $TG < 400$ mg/dL, is satisfied, as the given $TG$ is $250$ mg/dL. The problem is well-posed, providing all necessary information for a unique solution. Therefore, the problem is deemed valid.\n\nWe proceed to the calculation of $LDL$. The relationship between the cholesterol fractions is given as:\n$$TC \\approx LDL + HDL + VLDL$$\nWe can rearrange this equation to solve for $LDL$:\n$$LDL \\approx TC - HDL - VLDL$$\nThe problem provides the formula to estimate $VLDL$ from triglycerides:\n$$VLDL = \\frac{TG}{5}$$\nThis approximation is valid since $TG = 250$ mg/dL, which is less than the $400$ mg/dL threshold.\nFirst, we calculate the $VLDL$ concentration:\n$$VLDL = \\frac{250}{5} = 50 \\, \\text{mg/dL}$$\nNow, we can substitute the values of $TC$, $HDL$, and the calculated $VLDL$ into the equation for $LDL$:\n$$LDL \\approx 280 - 40 - 50$$\n$$LDL \\approx 240 - 50$$\n$$LDL \\approx 190 \\, \\text{mg/dL}$$\nThe calculated low-density lipoprotein cholesterol level is $190$ mg/dL.\n\nNext, we must infer the most likely xanthoma subtype. This requires correlating the clinical presentation and the lipid profile with known clinicopathologic entities.\nThe lipid profile is:\n- $TC = 280$ mg/dL (High; desirable is $< 200$)\n- $LDL = 190$ mg/dL (Very High; desirable is $< 100$, high is $\\ge 160$)\n- $HDL = 40$ mg/dL (Borderline low)\n- $TG = 250$ mg/dL (High; desirable is $< 150$)\nThis profile indicates a mixed hyperlipidemia, with a predominant and severe elevation in LDL cholesterol.\n\nThe clinical findings are:\n- Yellow papules on extensor surfaces.\n- Subtle thickening of the Achilles tendon.\n\nLet us evaluate the options based on these findings:\n- **Eruptive xanthomas (Code 2)** are classically associated with severe hypertriglyceridemia, typically with $TG$ levels exceeding $1000$ mg/dL. The patient's $TG$ level of $250$ mg/dL, while high, is not in the range typically seen with eruptive xanthomas.\n- **Tuberous xanthomas (Code 3)** are firm, painless, yellow nodules that can occur over extensor surfaces and pressure points. They are associated with elevated LDL, as seen in familial hypercholesterolemia.\n- **Planar xanthelasma palpebrarum (Code 4)** are yellow plaques confined to the eyelids and periorbital area. The patient's lesions are described on extensor surfaces, not the eyelids.\n- **Tendinous xanthomas (Code 1)** are lipid deposits within tendons, most characteristically the Achilles tendon and the extensor tendons of the hands. They manifest as slowly enlarging subcutaneous nodules or tendon thickening. Their presence is considered virtually pathognomonic for familial hypercholesterolemia, a genetic disorder characterized by extremely high levels of LDL cholesterol from birth.\n\nThe patient's presentation includes Achilles tendon thickening, a specific and strong indicator of tendinous xanthomas. This clinical sign, combined with a very high calculated LDL level of $190$ mg/dL, makes tendinous xanthoma the most likely diagnosis. The \"yellow papules on extensor surfaces\" could be consistent with tuberous xanthomas, which can coexist with tendinous xanthomas in severe hypercholesterolemia, but the Achilles tendon finding points most specifically to the tendinous subtype. Therefore, we select option $1$.\n\nThe final answer requires a $1 \\times 2$ matrix containing the $LDL$ value and the subtype code.\nThe computed $LDL$ is $190$.\nThe inferred subtype code is $1$.\nThe resulting matrix is $\\begin{pmatrix} 190 & 1 \\end{pmatrix}$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 190 & 1 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "While estimating $LDL$ cholesterol is a routine first step, a true expert understands the limitations of their tools. This exercise challenges you to move beyond simple calculation and explore the biochemical assumptions that underpin the Friedewald equation . By analyzing a clinical scenario involving severe hypertriglyceridemia, you will learn to identify situations where the formula fails and recognize the appropriate next steps for accurate lipid assessment.",
            "id": "4500431",
            "problem": "A $36$-year-old individual with poorly controlled type $2$ diabetes mellitus presents with a two-week history of crops of yellow papules on the buttocks and extensor surfaces; dermoscopy and histology are consistent with eruptive xanthomas. A fasting lipid profile shows total cholesterol $TC = 280$ mg/dL, high-density lipoprotein cholesterol (HDL-C) $= 24$ mg/dL, and triglycerides $TG = 1{,}120$ mg/dL. The clinician considers whether low-density lipoprotein cholesterol (LDL-C) can be estimated from the routine lipid panel. Starting from the fundamental conservation of cholesterol across lipoprotein classes and the typical biochemical composition of very-low-density lipoproteins (VLDL), derive the assumptions that permit estimation of LDL-C from routine lipids and identify conditions under which this estimation fails. Then decide, for this patient with eruptive xanthomas, which recommended next steps are appropriate. Which of the following statements are correct?\n\nA. In the fasting state with $TG < 400$ mg/dL and minimal chylomicrons, assuming a relatively constant VLDL cholesterol-to-triglyceride mass ratio, LDL-C can be estimated from conservation of total cholesterol; this is the core assumption underpinning the calculation.\n\nB. The estimation remains accurate in severe hypertriglyceridemia because VLDL particle composition is invariant; therefore eruptive xanthomas do not impact the validity of the calculation.\n\nC. Type III hyperlipoproteinemia (familial dysbetalipoproteinemia), classically associated with palmar xanthomas, causes failure of the estimation because intermediate-density lipoproteins contribute cholesterol to the non-high-density lipoprotein pool that is not appropriately partitioned by a fixed triglyceride factor.\n\nD. In nonfasting samples, postprandial chylomicrons increase $TG$ and VLDL proportionately, preserving the VLDL cholesterol-to-triglyceride ratio; thus the estimation remains valid.\n\nE. When $TG > 400$ mg/dL or when chylomicronemia is suspected (as in eruptive xanthomas), recommended actions include obtaining a direct LDL-C measurement or using alternative approaches such as apolipoprotein B quantification or calculations with an adjustable triglyceride-to-VLDL factor (for example, the Martin-Hopkins or Sampson methods).",
            "solution": "The problem statement is scientifically valid and well-posed. It describes a classic clinical presentation of severe hypertriglyceridemia (eruptive xanthomas secondary to poorly controlled diabetes mellitus) and asks for an analysis of low-density lipoprotein cholesterol (LDL-C) estimation.\n\n### Derivation of LDL-C Estimation and its Limitations\n\nThe estimation of LDL-C from a standard lipid panel is based on the principle of conservation of mass for cholesterol distributed among different lipoprotein classes.\n\n1.  **Fundamental Principle**: Total cholesterol ($TC$) measured in the plasma is the sum of the cholesterol content of its constituent lipoprotein fractions. The major classes are high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and chylomicrons. This can be expressed as:\n    $$TC = \\text{HDL-C} + \\text{LDL-C} + \\text{VLDL-C} + \\text{IDL-C} + \\text{Chylomicron-C}$$\n\n2.  **Assumptions for Estimation (leading to the Friedewald Equation)**: To create a simple, practical estimation for LDL-C, several key assumptions are made:\n    *   **Assumption 1: Fasting State.** The blood sample is drawn after a fast of $8$ to $12$ hours. This is intended to clear the plasma of chylomicrons, which transport dietary fat. Under this assumption, the contribution of chylomicron cholesterol ($\\text{Chylomicron-C}$) is considered negligible and can be set to zero. The equation simplifies to:\n        $$TC \\approx \\text{HDL-C} + \\text{LDL-C} + \\text{VLDL-C} + \\text{IDL-C}$$\n    *   **Assumption 2: Negligible IDL-C.** In most individuals, IDL is a transient particle with a short half-life and is present in low concentrations. The Friedewald formula operationally groups the cholesterol contribution from IDL with that of VLDL.\n    *   **Assumption 3: Constant VLDL Composition.** This is the central biochemical assumption. It posits that, in a fasting state, the mass ratio of triglycerides ($TG$) to cholesterol within VLDL particles is relatively constant across a population. Empirically, this ratio was determined to be approximately $5:1$. Furthermore, in a fasting state, the vast majority of plasma triglycerides are carried in VLDL. Therefore, the total measured plasma triglyceride concentration ($TG$) can be used as a surrogate for VLDL-triglyceride concentration. This allows for the estimation of VLDL-cholesterol (VLDL-C):\n        $$\\text{VLDL-C (mg/dL)} \\approx \\frac{\\text{Total } TG \\text{ (mg/dL)}}{5}$$\n        This fixed factor of $5$ is the linchpin of the Friedewald equation.\n\n3.  **The Friedewald Equation**: By substituting these assumptions into the conservation equation, we can rearrange to solve for LDL-C:\n    $$TC \\approx \\text{HDL-C} + \\text{LDL-C} + \\frac{TG}{5}$$\n    $$\\text{LDL-C}_{\\text{estimated}} = TC - \\text{HDL-C} - \\frac{TG}{5}$$\n\n4.  **Conditions for Failure**: The validity of the estimation hinges on its assumptions. The method fails when these assumptions are violated:\n    *   **Severe Hypertriglyceridemia ($TG > 400$ mg/dL)**: At high triglyceride levels, VLDL particles become larger and more enriched with triglycerides relative to cholesterol. The true $TG$-to-VLDL-C ratio is no longer $5:1$ but can be significantly higher. Using the fixed factor of $5$ overestimates the VLDL-C, which in turn leads to a factitiously low, or even negative, calculated LDL-C. The patient's $TG$ of $1{,}120$ mg/dL is far beyond this limit.\n    *   **Presence of Chylomicrons**: This occurs in the non-fasting state or in pathological conditions like familial chylomicronemia syndrome. Chylomicrons are extremely triglyceride-rich (e.g., $TG:C$ ratio of $10:1$ to $20:1$). Their presence adds to the total $TG$ measurement without a proportional increase in cholesterol, invalidating the use of a fixed $TG/5$ factor. The patient's eruptive xanthomas are a strong clinical indicator of chylomicronemia, even in the fasting state.\n    *   **Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)**: In this condition, an accumulation of cholesterol-enriched remnant particles (IDL and chylomicron remnants, collectively called $\\beta$-VLDL) occurs. These particles have a lower $TG$-to-cholesterol ratio than typical VLDL. Applying the $TG/5$ formula underestimates the cholesterol contribution from these remnant lipoproteins, leading to a falsely elevated LDL-C calculation.\n\n### Clinical Application and Next Steps for the Patient\n\nThe patient presents with a triglyceride level of $1{,}120$ mg/dL, which is considered severe hypertriglyceridemia. Furthermore, the presence of eruptive xanthomas strongly suggests the presence of chylomicronemia. Both conditions ($TG > 400$ mg/dL and chylomicronemia) are absolute contraindications for using the Friedewald equation. Therefore, an estimated LDL-C would be highly inaccurate and clinically misleading. The appropriate next step is to use a method that does not rely on the flawed assumptions of the Friedewald equation. Recommended actions include obtaining a direct LDL-C measurement (via immunoseparation or ultracentrifugation), measuring Apolipoprotein B (ApoB) to quantify the total number of atherogenic particles, or using more advanced calculations (e.g., Martin-Hopkins) that employ an adjustable factor for VLDL-C estimation.\n\n### Evaluation of Options\n\n**A. In the fasting state with $TG < 400$ mg/dL and minimal chylomicrons, assuming a relatively constant VLDL cholesterol-to-triglyceride mass ratio, LDL-C can be estimated from conservation of total cholesterol; this is the core assumption underpinning the calculation.**\nThis statement accurately summarizes the foundational principles and conditions of validity for the Friedewald equation. It correctly lists the fasting state, a triglyceride threshold ($TG < 400$ mg/dL), the absence of chylomicrons, and the critical assumption of a constant VLDL cholesterol-to-triglyceride ratio.\n**Verdict: Correct.**\n\n**B. The estimation remains accurate in severe hypertriglyceridemia because VLDL particle composition is invariant; therefore eruptive xanthomas do not impact the validity of the calculation.**\nThis statement is factually incorrect on all points. The estimation fails in severe hypertriglyceridemia precisely because VLDL particle composition is *not* invariant; the particles become more triglyceride-rich. Eruptive xanthomas are a clinical sign of the very conditions (severe hypertriglyceridemia and chylomicronemia) that invalidate the calculation.\n**Verdict: Incorrect.**\n\n**C. Type III hyperlipoproteinemia (familial dysbetalipoproteinemia), classically associated with palmar xanthomas, causes failure of the estimation because intermediate-density lipoproteins contribute cholesterol to the non-high-density lipoprotein pool that is not appropriately partitioned by a fixed triglyceride factor.**\nThis statement correctly identifies Type III hyperlipoproteinemia as a cause of estimation failure. It accurately links the condition to palmar xanthomas and provides the correct underlying mechanism: the accumulation of cholesterol-rich remnant particles (IDL) whose cholesterol content is not appropriately estimated by the fixed $TG/5$ factor, leading to an overestimation of LDL-C.\n**Verdict: Correct.**\n\n**D. In nonfasting samples, postprandial chylomicrons increase $TG$ and VLDL proportionately, preserving the VLDL cholesterol-to-triglyceride ratio; thus the estimation remains valid.**\nThis statement is incorrect. The presence of chylomicrons from a meal invalidates the estimation. Chylomicrons and VLDL are distinct lipoprotein classes and do not increase proportionately. The large influx of chylomicron-associated triglycerides, which have a very high $TG:C$ ratio, invalidates the assumption that total $TG$ can be used to estimate VLDL-C with a fixed factor of $5$.\n**Verdict: Incorrect.**\n\n**E. When $TG > 400$ mg/dL or when chylomicronemia is suspected (as in eruptive xanthomas), recommended actions include obtaining a direct LDL-C measurement or using alternative approaches such as apolipoprotein B quantification or calculations with an adjustable triglyceride-to-VLDL factor (for example, the Martin-Hopkins or Sampson methods).**\nThis statement correctly identifies the patient's clinical situation ($TG = 1{,}120$ mg/dL, eruptive xanthomas) as a contraindication for the standard estimation. It then lists the appropriate, evidence-based next steps for management: direct LDL-C measurement, ApoB quantification, or the use of newer, more robust formulas like the Martin-Hopkins or Sampson methods. This is the standard of care.\n**Verdict: Correct.**",
            "answer": "$$\\boxed{ACE}$$"
        },
        {
            "introduction": "Many xanthomatoses, particularly tendon xanthomas, are sentinel markers for underlying genetic disorders like familial hypercholesterolemia (FH). Managing FH extends beyond the individual to the entire family, requiring a firm grasp of genetic principles and risk communication. This advanced problem requires you to apply Mendelian inheritance, Bayes’ theorem, and concepts of disease penetrance to quantify the risk for a patient's offspring . Successfully navigating this scenario demonstrates the ability to translate complex genetic and probabilistic data into tangible clinical guidance.",
            "id": "4500505",
            "problem": "A 38-year-old individual presents with multiple firm tendon xanthomas on the Achilles and extensor tendons. Genetic testing confirms a pathogenic heterozygous variant in the Low-Density Lipoprotein Receptor (LDLR) gene. They plan to have four children with a 30-year-old partner whose fasting Low-Density Lipoprotein Cholesterol (LDL-C) measurements have been consistently within the normal range for age on two separate occasions. There is no reported family history of premature atherosclerotic cardiovascular disease in the partner’s first-degree relatives. You are asked to construct a pedigree-based quantitative risk for the children being clinically affected with familial hypercholesterolemia by late adolescence and to compute the expected number of affected children among four.\n\nUse the following scientifically supported foundations and assumptions:\n- Familial hypercholesterolemia due to a pathogenic LDLR variant is inherited in an autosomal dominant manner. A heterozygous parent transmits the pathogenic allele to each child with probability $1/2$.\n- Define “affected by late adolescence” as meeting a clinically relevant familial hypercholesterolemia phenotype by approximately age $18$ (e.g., LDL-C elevation in the familial hypercholesterolemia range and/or detection of tendon xanthomas by imaging). In heterozygous carriers, age-specific penetrance for being clinically affected by age $18$ is $p_{\\mathrm{het}} = 0.85$. In biallelic carriers (homozygous or compound heterozygous for LDLR pathogenic variants), penetrance by age $18$ is $p_{\\mathrm{bial}} = 0.99$. In non-carriers, the phenocopy probability (being “affected” due to non-genetic or non-LDLR causes by age $18$) is $q = 0.02$.\n- The background prevalence of a heterozygous familial hypercholesterolemia-causing pathogenic variant in the general population is $\\pi = \\frac{1}{250}$. Among true carriers by age $30$, the probability of having a normal LDL-C screening result is $f_{c} = 0.10$; among non-carriers, the probability of having a normal LDL-C screening result is $f_{n} = 0.95$.\n- Assume the partner’s potential pathogenic variant, if present, is independent of the proband’s variant and, if transmitted together, produces a biallelic state with penetrance $p_{\\mathrm{bial}}$. Assume random mating and independence of transmissions.\n\nTasks:\n1. Using Bayes’ theorem and the partner’s normal LDL-C screening result, compute the posterior probability that the partner is a heterozygous carrier of a pathogenic familial hypercholesterolemia variant.\n2. Using Mendelian transmission and the penetrance/phenocopy values above, compute the per-child probability of being clinically affected by age $18$, accounting for whether the partner is or is not a carrier.\n3. Compute the expected number of affected children out of four by multiplying the per-child probability by $4$.\n\nExpress your final answer as a single number equal to the expected number of affected children among four, rounded to four significant figures.",
            "solution": "The problem requires a multi-step quantitative risk assessment based on principles of medical genetics, Mendelian inheritance, and probability theory. The solution is structured to follow the three tasks outlined in the problem statement.\n\nFirst, we must validate the problem. The problem is scientifically grounded in the genetics of familial hypercholesterolemia (FH), an autosomal dominant disorder. The provided parameters, including inheritance patterns, population prevalence, penetrance, phenocopy rates, and probabilities associated with clinical screening, are well-defined and plausible. The problem is well-posed, with a clear objective and sufficient information to derive a unique solution. It is free of ambiguity and subjectivity. The problem is therefore deemed valid.\n\nLet $D$ represent the pathogenic (dominant) allele for familial hypercholesterolemia and $d$ represent the normal (wild-type) allele. The proband has a confirmed pathogenic heterozygous variant, so their genotype is $Dd$.\n\n**Task 1: Compute the posterior probability that the partner is a heterozygous carrier.**\n\nLet $C$ be the event that the partner is a heterozygous carrier (genotype $Dd$).\nLet $N$ be the event that the partner is not a carrier (genotype $dd$).\nLet $E$ be the evidence that the partner has a normal fasting LDL-C screening result.\n\nThe prior probabilities are based on the general population prevalence:\nThe probability that the partner is a carrier is $P(C) = \\pi = \\frac{1}{250} = 0.004$.\nThe probability that the partner is not a carrier is $P(N) = 1 - \\pi = 1 - \\frac{1}{250} = \\frac{249}{250} = 0.996$.\n\nThe conditional probabilities of the evidence (normal LDL-C) are given:\nThe probability of a normal LDL-C result, given the partner is a carrier, is $P(E|C) = f_{c} = 0.10$.\nThe probability of a normal LDL-C result, given the partner is not a carrier, is $P(E|N) = f_{n} = 0.95$.\n\nWe use Bayes' theorem to find the posterior probability that the partner is a carrier, given the normal LDL-C result, $P(C|E)$:\n$$P(C|E) = \\frac{P(E|C)P(C)}{P(E)}$$\nThe denominator, $P(E)$, is the total probability of observing the evidence, calculated using the law of total probability:\n$$P(E) = P(E|C)P(C) + P(E|N)P(N)$$\nSubstituting the values:\n$$P(E) = (0.10)\\left(\\frac{1}{250}\\right) + (0.95)\\left(\\frac{249}{250}\\right) = \\frac{0.10 + (0.95)(249)}{250} = \\frac{0.10 + 236.55}{250} = \\frac{236.65}{250} = 0.9466$$\nNow we can compute the posterior probability $P(C|E)$:\n$$P(C|E) = \\frac{(0.10)(1/250)}{0.9466} = \\frac{0.0004}{0.9466} \\approx 0.000422565$$\nThe posterior probability that the partner is not a carrier is $P(N|E) = 1 - P(C|E) \\approx 1 - 0.000422565 = 0.999577435$.\nAlternatively, $P(N|E) = \\frac{P(E|N)P(N)}{P(E)} = \\frac{(0.95)(249/250)}{0.9466} = \\frac{0.9462}{0.9466} \\approx 0.999577435$.\n\n**Task 2: Compute the per-child probability of being clinically affected.**\n\nLet $A_{\\text{child}}$ be the event that a child is clinically affected by age $18$. We compute this probability using the law of total probability, conditioned on the partner's carrier status using the posterior probabilities calculated in Task 1.\n$$P(A_{\\text{child}}) = P(A_{\\text{child}}|C) P(C|E) + P(A_{\\text{child}}|N) P(N|E)$$\n\nWe must first determine the conditional probabilities $P(A_{\\text{child}}|C)$ and $P(A_{\\text{child}}|N)$.\n\nCase 1: The partner is a carrier (genotype $Dd$). The genetic cross is $Dd \\times Dd$.\nThe probabilities of the offspring's genotypes are:\n- $P(\\text{genotype } DD) = 1/4$\n- $P(\\text{genotype } Dd) = 1/2$\n- $P(\\text{genotype } dd) = 1/4$\nThe probability of being affected for each genotype is given by the penetrance ($p_{\\mathrm{bial}}$, $p_{\\mathrm{het}}$) and phenocopy ($q$) rates:\n$P(A_{\\text{child}}|C) = P(A_{\\text{child}}|\\text{genotype } DD)P(\\text{genotype } DD) + P(A_{\\text{child}}|\\text{genotype } Dd)P(\\text{genotype } Dd) + P(A_{\\text{child}}|\\text{genotype } dd)P(\\text{genotype } dd)$\n$$P(A_{\\text{child}}|C) = (p_{\\mathrm{bial}})\\left(\\frac{1}{4}\\right) + (p_{\\mathrm{het}})\\left(\\frac{1}{2}\\right) + (q)\\left(\\frac{1}{4}\\right)$$\n$$P(A_{\\text{child}}|C) = (0.99)\\left(\\frac{1}{4}\\right) + (0.85)\\left(\\frac{1}{2}\\right) + (0.02)\\left(\\frac{1}{4}\\right) = 0.2475 + 0.425 + 0.005 = 0.6775$$\n\nCase 2: The partner is not a carrier (genotype $dd$). The genetic cross is $Dd \\times dd$.\nThe probabilities of the offspring's genotypes are:\n- $P(\\text{genotype } Dd) = 1/2$\n- $P(\\text{genotype } dd) = 1/2$\nThe probability of being affected is:\n$P(A_{\\text{child}}|N) = P(A_{\\text{child}}|\\text{genotype } Dd)P(\\text{genotype } Dd) + P(A_{\\text{child}}|\\text{genotype } dd)P(\\text{genotype } dd)$\n$$P(A_{\\text{child}}|N) = (p_{\\mathrm{het}})\\left(\\frac{1}{2}\\right) + (q)\\left(\\frac{1}{2}\\right)$$\n$$P(A_{\\text{child}}|N) = (0.85)\\left(\\frac{1}{2}\\right) + (0.02)\\left(\\frac{1}{2}\\right) = 0.425 + 0.01 = 0.435$$\n\nNow, we combine these results to find the total probability of a child being affected:\n$$P(A_{\\text{child}}) = (0.6775) \\cdot P(C|E) + (0.435) \\cdot P(N|E)$$\nUsing the values derived earlier:\n$$P(A_{\\text{child}}) = (0.6775)\\left(\\frac{0.0004}{0.9466}\\right) + (0.435)\\left(\\frac{0.9462}{0.9466}\\right)$$\n$$P(A_{\\text{child}}) = \\frac{(0.6775)(0.0004) + (0.435)(0.9462)}{0.9466} = \\frac{0.000271 + 0.411597}{0.9466} = \\frac{0.411868}{0.9466}$$\n$$P(A_{\\text{child}}) \\approx 0.435102472$$\n\n**Task 3: Compute the expected number of affected children out of four.**\n\nThe number of children is $n=4$. Each child's outcome is an independent trial with a probability of being affected $p = P(A_{\\text{child}})$. For a series of $n$ independent Bernoulli trials, the expected number of \"successes\" (affected children) is given by $E[X] = n \\cdot p$.\n$$E[X] = 4 \\times P(A_{\\text{child}})$$\n$$E[X] = 4 \\times 0.435102472 \\approx 1.740409888$$\nThe problem requires the answer to be rounded to four significant figures.\nThe value $1.740409888...$ rounded to four significant figures is $1.740$.",
            "answer": "$$\\boxed{1.740}$$"
        }
    ]
}